Videos

Panelists discuss how NK receptor antagonism provides a targeted, nonhormonal strategy that addresses the physiological root of vasomotor symptoms.

Panelists discuss how limited treatment options and systemic barriers underscore the urgent need for accessible, targeted therapies for vasomotor symptoms.

Panelists discuss how vasomotor symptoms undermine physical comfort, sleep, and long-term health, emphasizing integrative management to restore overall quality of life.

Panelists discuss how hormonal decline and KNDy neuron overactivation drive vasomotor symptoms and inform the development of targeted neurokinin receptor therapies.

An expert discusses how the stage and diverse presentations of atopic dermatitis, especially in underserved and darker-skinned patients, influence treatment decisions, highlighting the promise of new nonsteroidal therapies and the importance of personalized, patient-centered care to improve quality of life.

An expert discusses the vital role of patient education, coordinated care, and timely dermatology referrals in managing atopic dermatitis, emphasizing holistic support and the use of systemic therapies for severe or treatment-resistant cases to improve long-term outcomes.

An expert discusses the importance of careful topical steroid use to minimize adverse effects in atopic dermatitis, while highlighting newer, more potent nonsteroidal treatments such as PDE4 and JAK inhibitors as promising safer alternatives for effective long-term disease control.

An expert discusses the benefits and risks of topical corticosteroids (TCS) and calcineurin inhibitors in atopic dermatitis (AD) treatment, highlighting patient concerns about long-term adverse effects and withdrawal, while emphasizing emerging nonsteroidal therapies as promising safer alternatives for personalized care.

An expert discusses the shift from reactive to proactive treatment of atopic dermatitis (AD), emphasizing personalized care and the growing role of advanced nonsteroidal topicals—such as PDE4 and JAK inhibitors—alongside updated guidelines aimed at improving clinician awareness and patient outcomes.

An expert discusses proactive management strategies for atopic dermatitis (AD), emphasizing daily gentle skin care, proper use of topical treatments, avoidance of outdated therapies such as routine antihistamines or steroids, and a shift toward personalized, flare-preventive care using newer therapeutic options.

An expert discusses practical strategies for assessing atopic dermatitis severity, highlighting simple yet effective tools such as the Investigator Global Assessment (IGA) scale, palm-based body surface area (BSA) estimation, and the Pruritus Numerical Rating Scale (NRS) to guide personalized treatment and improve symptom tracking in routine clinical care.

An expert discusses the formal diagnostic criteria and diverse clinical presentations of atopic dermatitis, emphasizing patient-centered assessment, challenges in distinguishing it from similar conditions, and the critical role of education and skin care in effective management, particularly in primary care settings.

An expert discusses advancements in the management of atopic dermatitis, emphasizing early recognition, updated nonsteroidal treatments, accurate differential diagnosis, and the importance of collaboration between dermatology and primary care providers to improve patient outcomes.

A panelist emphasizes that shared decision-making in anaphylaxis management is essential, combining evidence-based guidelines with individual patient circumstances and preferences—especially regarding newer options like intranasal epinephrine—to ensure timely, confident use while addressing practical concerns, such as access, cost, and education.

A panelist highlights how neffy, a needle-free, portable intranasal epinephrine device, addresses key unmet needs by reducing needle anxiety, enabling easy use by nonmedical caregivers, offering longer shelf life and temperature stability, and improving timely administration to prevent severe anaphylaxis outcomes, as demonstrated in clinical case examples.

A panelist discusses that the intranasal epinephrine device causes only mild, expected adverse effects such as nasal discomfort and headache, avoids injection-related risks, demonstrates rapid symptom improvement in pediatric food challenge studies, and offers practical advantages such as higher heat tolerance for storage and a longer shelf life compared with traditional autoinjectors.

A panelist discusses a newly approved intranasal epinephrine device for treating anaphylaxis in both children and adults, highlighting its needle-free delivery using a nasal spray with an absorption enhancer that ensures effective, safe drug uptake comparable to injections—even under nasal congestion—offering a promising alternative to traditional epinephrine autoinjectors.

A panelist discusses how intranasal epinephrine represents a significant advance over traditional autoinjectors by eliminating needles, addressing user anxiety and real-world barriers, and potentially improving adherence and timely treatment in anaphylaxis emergencies.

A panelist discusses how barriers such as cost, fear of injections, and lack of confidence delay epinephrine use in anaphylaxis and explains how intranasal delivery and updated guidelines may reduce hesitation and improve timely, effective treatment through better education and accessibility.

A panelist discusses the critical importance of early epinephrine administration in anaphylaxis for preventing severe outcomes, explaining its multireceptor action and lifesaving potential, while highlighting how intranasal delivery could enhance timely use and empower caregivers with faster, more accessible treatment options.

A panelist discusses how intranasal epinephrine could transform anaphylaxis management by improving accessibility, reducing treatment delays, and addressing underuse of epinephrine—especially in pediatric and high-risk populations—while emphasizing the need for better education and more user-friendly interventions to improve outcomes.

Panelists discuss billing and coding procedures for skin scanning devices, focusing on the use of unlisted Current Procedural Terminology (CPT) 99 codes with proper documentation and modifiers, the importance of clear communication with billing teams, available educational resources to aid primary care settings, and operational considerations including scope-of-practice variations for device use among clinical staff.

Panelists discuss an interactive case session emphasizing the nuanced evaluation of suspicious skin lesions, highlighting tools such as the DermaSensor for risk scoring, the ugly duckling concept, and the importance of combining clinical judgment with technology to guide biopsy decisions and patient follow-up across diverse skin types.

Panelists discuss that decisions to forgo biopsy often weigh patient risk and lesion characteristics with noninvasive tools offering valuable reassurance; while familiarity with artificial intelligence (AI) aids varies, these technologies—used judiciously and alongside clinical expertise—can boost diagnostic confidence, though limitations and integration challenges remain.